HTL launches new CSR strategy
BMG Pharma & HTL sign a development agreement to manufacture BMG’s new biopolymer based on the Hyaluromimethic® Technology
HTL team in Korea and China to meet their clients and expend business
HTL, winner of the special jury prize at the CCI France International Trophy
HTL accelerates its development strategy with the appointment of François Fournier as CEO from Sep 1st, 2022
JAVENÉ, France, March 10, 2022 /PRNewswire/ -- HTL Biotechnology, a pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, today announced its incubator's first equity investment in GelMEDIX Inc., an early-stage biotechnology company committed to developing the next generation of ocular and regenerative therapies.
HTL announces Montagu as new investor alongside its historical shareholders, Naxicap and Téthys Invest
HTL launches a new, cutting-edge bioproduction unit for pharmaceutical-grade biopolymers
Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion's exclusive botulinum active pharmaceutical ingredient (API) manufacturer.
LOS ANGELES, May 7, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI), a research institute at the frontier of personalized and precision medicine, and HTL Biotechnology, the world leader in using hyaluronic acid and other biopolymers for biotechnology solutions, announce their Memorandum of Understanding to explore the creation of a joint research program. This program focuses on biomaterials for translational projects; it would combine TIBI's microneedle and bioprinting technologies with HTL's expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.